adalimumab
Commercial- Indications
- Rheumatoid arthritis, Psoriatic arthritis
Company intelligence / Profile preview
Cambridge Antibody Technology
Cambridge, Cambridgeshire, United Kingdomen.wikipedia.org ↗
- Ownership
- Private
- Employees
- ~300
- Development stage
- Commercial
01
Overview
Discovered adalimumab (Humira), the first fully human antibody blockbuster drug for treating rheumatoid arthritis. Also discovered belimumab (Benlysta), the first new approved drug for systemic lupus in more than 50 years.
- Therapeutic areas
- Immunology
- Modalities
- Monoclonal antibodiesfully human antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
BASF Pharma (Knoll Pharmaceuticals)Abbott Laboratories
Beyond the preview
Go deeper on Cambridge Antibody Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cambridge Antibody Technology.